Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3NET 1Endocrine 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Neuroendocrine Tumors 1Kidney Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Ifosfamide 2Filgrastim 2Doxorubicin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1pentetreotide 1guadecitabine 1gallium Ga 68 dotatate 1fostamatinib 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Microscopy, Electron 1Lenalidomide 1Immunotherapy 1Genetic Testing 1Everolimus 1Drug Therapy 1Cyclophosphamide 1Chemotherapy, Adjuvant 1CYT-6091 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Lenalidomide × Endocrine × Clear all
NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Emory University

Phase 1 Completed
44 enrolled 9 charts
EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡